$RARE
Ultragenyx Pharmaceutical Inc.

2014 Q3 Form 10-Q Financial Statement

#000156459014005413 Filed on November 10, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2013 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.980M $1.000M
YoY Change 198.0% 3.09%
% of Gross Profit
Research & Development $12.85M $6.760M
YoY Change 90.09% 83.7%
% of Gross Profit
Depreciation & Amortization $190.0K $100.0K
YoY Change 90.0% 11.11%
% of Gross Profit
Operating Expenses $15.84M $7.761M
YoY Change 104.03% 67.26%
Operating Profit
YoY Change
Interest Expense $170.0K $70.00K
YoY Change 142.86%
% of Operating Profit
Other Income/Expense, Net -$14.00K -$667.0K
YoY Change -97.9% -6770.0%
Pretax Income -$15.85M -$8.430M
YoY Change 88.02% 82.07%
Income Tax
% Of Pretax Income
Net Earnings -$15.85M -$8.428M
YoY Change 88.05% 82.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$501.1K -$290.1K
COMMON SHARES
Basic Shares Outstanding 3.622M
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $201.2M $63.70M
YoY Change 215.86%
Cash & Equivalents $53.39M $6.049M
Short-Term Investments $147.8M $57.60M
Other Short-Term Assets $5.500M $3.000M
YoY Change 83.33%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $206.7M $66.70M
YoY Change 209.9%
LONG-TERM ASSETS
Property, Plant & Equipment $2.600M $1.300M
YoY Change 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.600M $600.0K
YoY Change 166.67%
Total Long-Term Assets $4.200M $1.900M
YoY Change 121.05%
TOTAL ASSETS
Total Short-Term Assets $206.7M $66.70M
Total Long-Term Assets $4.200M $1.900M
Total Assets $210.9M $68.60M
YoY Change 207.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.200M $2.900M
YoY Change 44.83%
Accrued Expenses $6.800M $2.600M
YoY Change 161.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.10M $5.600M
YoY Change 98.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $1.800M
YoY Change -72.22%
Total Long-Term Liabilities $500.0K $1.800M
YoY Change -72.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.10M $5.600M
Total Long-Term Liabilities $500.0K $1.800M
Total Liabilities $11.60M $7.400M
YoY Change 56.76%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $199.3M $61.20M
YoY Change
Total Liabilities & Shareholders Equity $210.9M $68.60M
YoY Change 207.43%

Cashflow Statement

Concept 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$15.85M -$8.428M
YoY Change 88.05% 82.03%
Depreciation, Depletion And Amortization $190.0K $100.0K
YoY Change 90.0% 11.11%
Cash From Operating Activities -$11.03M -$6.750M
YoY Change 63.41% 92.86%
INVESTING ACTIVITIES
Capital Expenditures -$440.0K -$200.0K
YoY Change 120.0% 900.0%
Acquisitions
YoY Change
Other Investing Activities -$13.10M -$580.0K
YoY Change 2158.62% 480.0%
Cash From Investing Activities -$13.55M -$790.0K
YoY Change 1615.19% 558.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.51M 70.00K
YoY Change 86342.86% -99.54%
NET CHANGE
Cash From Operating Activities -11.03M -6.750M
Cash From Investing Activities -13.55M -790.0K
Cash From Financing Activities 60.51M 70.00K
Net Change In Cash 35.93M -7.470M
YoY Change -580.99% -164.34%
FREE CASH FLOW
Cash From Operating Activities -$11.03M -$6.750M
Capital Expenditures -$440.0K -$200.0K
Free Cash Flow -$10.59M -$6.550M
YoY Change 61.68% 88.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3621654
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2444000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-972000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1501000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58847000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
133000
us-gaap Investment Income Interest
InvestmentIncomeInterest
157000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1155000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-667000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3229000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-998000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
160942000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
63056000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1823000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
3003000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
53509000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4462000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
293000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106419000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
186620000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
4346000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
182274000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
133000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
45960000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-80141000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86190000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6049000
us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
6743000
CY2014Q3 us-gaap Excess Stock Shares Authorized
ExcessStockSharesAuthorized
275000000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1613879
CY2014Q3 rare Purchase Of Additional Shares By Underwriters From Public Offering
PurchaseOfAdditionalSharesByUnderwritersFromPublicOffering
302602
CY2014Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
40.00
CY2014Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
706072
CY2014Q3 rare Proceeds From Issuance Of Public Offering Gross
ProceedsFromIssuanceOfPublicOfferingGross
60700000
CY2014Q3 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
3900000
CY2014Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
400000
CY2014Q3 rare Net Proceeds From Issuance Of Public Offering
NetProceedsFromIssuanceOfPublicOffering
60200000
CY2014Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3190
CY2014Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
194939000
CY2013Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
52797000
CY2013Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
3419000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3419000
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
518000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
3324000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1078000
CY2013Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1596000
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
195057000
CY2014Q3 rare Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
9000
CY2014Q3 rare Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
127000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
194939000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
52786000
CY2013Q4 rare Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
17000
CY2013Q4 rare Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
6000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
52797000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014Q3 rare Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
3352000
CY2013Q4 rare Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
1886000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2974000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2360000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
505000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
160000
CY2013Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
3400000
CY2014Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
19598486
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
71000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3393000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
447000
CY2014Q3 us-gaap Purchase Obligation
PurchaseObligation
479000
CY2013Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
4162000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
4808000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3529264
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27697137
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
7871000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
268780
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21663612
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5053258
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21820583

Files In Submission

Name View Source Status
0001564590-14-005413-index-headers.html Edgar Link pending
0001564590-14-005413-index.html Edgar Link pending
0001564590-14-005413.txt Edgar Link pending
0001564590-14-005413-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201411102057247501875.jpg Edgar Link pending
g201411102057504351574.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rare-10q_20140930.htm Edgar Link pending
rare-20140930.xml Edgar Link completed
rare-20140930.xsd Edgar Link pending
rare-20140930_cal.xml Edgar Link unprocessable
rare-20140930_def.xml Edgar Link unprocessable
rare-20140930_lab.xml Edgar Link unprocessable
rare-20140930_pre.xml Edgar Link unprocessable
rare-ex101_20140930241.htm Edgar Link pending
rare-ex311_20140930238.htm Edgar Link pending
rare-ex312_20140930239.htm Edgar Link pending
rare-ex321_20140930240.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending